Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
M.D. Anderson Cancer Center
Thomas Jefferson University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Massachusetts General Hospital
University of California, Davis
City of Hope Medical Center
University of Washington
Thomas Jefferson University
City of Hope Medical Center
Incyte Corporation
University of Miami
University of Washington
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Massachusetts General Hospital
Thomas Jefferson University
Celgene
SCRI Development Innovations, LLC
Thomas Jefferson University
Wake Forest University Health Sciences
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Incyte Corporation
Fred Hutchinson Cancer Center
City of Hope Medical Center
Juno Therapeutics, a Subsidiary of Celgene
National Cancer Institute (NCI)
ADC Therapeutics S.A.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Washington
Fred Hutchinson Cancer Center
MEI Pharma, Inc.
Celgene
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Wisconsin, Madison
University of Miami
Bayer
Novartis